Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges.

摘要: The availability of several potent antifungal agents, systemic or topical, over the counter prescription would suggest that therapeutic needs for Candida vaginitis are minimal absent. Unfortunately, unmet still exist. Moreover, pharmaceutical industry has abandoned and no new agents studies imminent. Perhaps most important advance in last decade been recognition therapy must be individualized not all forms equal. A critical factor is duration need maintenance recurrent candidiasis. In addition, serious deficiencies exist C. glabrata vaginitis, an emerging problem. Azole frequently fails, depleting armamentarium successful options. Additional challenges remain women who can easily controlled but cured with intensive azole spite absence vitro resistance. Any non-drug related will require a better understanding immunopathogenesis VVC effective naturally occurring host protective mechanisms. Copyright 1999 Harcourt Publishers Ltd.